Authors :
Presenting Author: Hua Zhang, MD, PhD – The First Affiliated Hospital of Xi’an Jiaotong University
Yong Liu, MMS， Neurosurgeon – The First Affiliated Hospital of Xi’an Jiaotong University; Huanfa Li, BM, EEG technician – The First Affiliated Hospital of Xi’an Jiaotong University; Qiang Meng, MMS， Neurosurgeon – The First Affiliated Hospital of Xi’an Jiaotong University
Rationale: Functional anterior temporal lobectomy (FATL), firstly reported by our center, is a minimally invasive surgery for temporal lobe epilepsy (TLE).
1 Herein, we report the two year outcome of FATL for TLE.
Methods: Patients with drug refractory TLE undergoing FATL from October 2020 to May 2021 were collected. The last follow-up was performed at May 2023. Seizure outcomes were classified by Engel classification. Study outcomes included seizure-freedom rate, seizure-remission rate after FATL. Kaplan-Meier curve of seizure-freedom was also drawed.
Results: There were 21 consecutive patients receiving FATL for TLE. Table 1 shows the patients characteristics in this study. The mean follow-up duration was 27.4 months. There were 16 (76.2%) patients with Engel I seizure outcome (Ia: 12 patients, Ic: 2 patients, Id: 2 patients) after FATL, 2 patients 9.5%) with Engel IIb, 3 patient (14.3%) with Engel III. One-year and 2-year remission rate were 85.7% (18/21) and 76.2% (16/21), respectively. Figure 1 shows the Kaplan-Meier curve of seizure-freedom over time after FATL.
Conclusions: Our study suggests that FATL has excellent outcomes for treating TLE, comparable to the outcomes of anterior temporal lobectomy. A prospective controlled trial is appealed to compare the seizure outcomes between FATL and anterior temporal lobectomy.
Funding: No funding